Yuan Yuyu, deputy to the National People’s Congress and chairman of Medprin Regenerative Medical Technologies Co.Ltd(301033) board, said in an interview with the reporter of China Securities Journal that it is suggested to support leading enterprises in subdivided fields to build their own supply chain system, encourage Chinese medical device suppliers to innovate independently and build a diversified industrial chain; At the same time, promote the establishment of the main responsibility of medical institutions in the clinical and application of innovative products, encourage innovative products to be hung up in the national network, and sink into the market as soon as possible.
ensure the safety and stability of medical device supply chain
The safety and stability of the supply chain is an important guarantee for the high-quality development of the medical device industry chain. For example, Yuan Yuyu said, “if supply is the ‘chassis’ of industrial chain development, innovation is the’ transmission shaft ‘. The’ chassis’ is unstable, which makes it difficult to build a high-quality development pattern of medical device industrial chain. The ‘transmission shaft’ has insufficient power, and it is difficult to stabilize and achieve a high-quality development pattern.”
At present, the supply chain security and competitiveness of China’s medical device industry are facing many challenges. On the one hand, most medical device enterprises are highly dependent on imports for parts, key equipment and raw materials, and the independent R & D capacity of key technologies needs to be strengthened; On the other hand, the strategic resource reserve of Chinese suppliers is limited. At present, the number of enterprises engaged in independent research and development of key parts and components and key raw materials in China is small, and there is a shortage of suppliers who can meet the product development requirements of medical devices. In addition, most of China’s medical scientific and technological innovation achievements have not yet been industrialized, and the conversion rate of medical device scientific research achievements is less than 8%, which is far from nearly 70% in the United States and Japan.
In order to solve the problem of “two skins” between innovation and industry, Yuan Yuyu suggested to explore the establishment of project classification (such as scientific research group and enterprise group) evaluation and classification support mechanism under the guidance of market demand, promote the accurate influx of resources into key fields and weak links of industry, and encourage enterprises to take the lead in establishing innovation consortia to improve enterprises, universities, clinical Cooperation mechanism of “industry university research medicine” between scientific research institutions. At the same time, encourage science and technology-based private enterprises to undertake or participate in major science and technology research projects such as key R & D plans, and give certain support to such projects, so as to fully release the industry’s guidance and undertaking capacity for innovation.
In addition, he suggested supporting leading enterprises in subdivided fields to build their own supply chain system, encouraging Chinese medical device suppliers to innovate independently, building a diversified industrial chain supply strategy, and supporting enterprises, colleges and universities to jointly carry out research and development of independent innovation technology in the supply chain through industrial innovation research institutes, so as to open up the whole industrial chain and prevent the risk of supply chain interruption from the source of technology.
improve Innovation Medical Management Co.Ltd(002173) instrument products
market access protection mechanism
China’s medical device industry has made great progress in recent years, but the localization rate of products in the field of high-performance medical devices is low, and there are still obvious bottlenecks in related products, core components and key technologies. In addition, the domestic innovative products of high-performance medical devices have a long cycle from R & D to listing.
In view of the industrial innovation of high-performance medical devices and related market mechanism problems, Yuan Yuyu suggested to implement the main responsibility of medical institutions in the clinical and application of innovative products, and strengthen the support of online centralized purchase and medical insurance funds. Specifically, by screening large academic, specialized and comprehensive medical institutions as clinical research bases for innovative products, or exploring the pilot mechanism for the clinical use of innovative products in medical institutions, we can promote the market-oriented application and further innovation of innovative products.
He also suggested that innovative products should be encouraged to hang up in the national network and sink into the market as soon as possible; In the distribution proportion of the quantity of products purchased with quantity, strive to leave more than 20% space for domestic innovative products; During the implementation of DRG (disease diagnosis related group), 20% of the medical insurance fund is allocated for innovative products.
In order to improve the market access protection mechanism of Innovation Medical Management Co.Ltd(002173) device products, the State Food and drug administration has deeply implemented the Innovation Medical Management Co.Ltd(002173) device priority review and approval policy in recent years to improve the listing speed of Innovation Medical Management Co.Ltd(002173) device products. According to the medical device report of the State Food and drug administration, it received 249 applications for special approval of Innovation Medical Management Co.Ltd(002173) devices in 2021, with a year-on-year increase of 26.4%.
In addition, the “green channel” mechanism for market access of innovative medical devices has also been implemented in some provinces, autonomous regions and cities in the past two years. Yuan Yuyu introduced that at the end of 2021, Jiangsu Province issued a new policy of “optimizing the review and approval service and promoting the use of innovative drugs and equipment”, establishing a green channel for online listing of innovative drug consumables and promoting the first time listing and sales of innovative products; At the beginning of 2022, Heilongjiang Medical Insurance Bureau issued the notice on further improving the online procurement of medical consumables in Heilongjiang Province (Draft for comments), establishing a green channel for innovative products to be online at any time.
\u3000
